1 0 1 0 1 B-lower_bound
year-50 2 9 2 9 I-lower_bound
years 10 15 10 15 I-upper_bound

> 0 1 16 17 O
6 2 3 18 19 B-lower_bound
months 4 10 20 26 I-lower_bound
must 11 15 27 31 O
have 16 20 32 36 O
elapsed 21 28 37 44 O
from 29 33 45 49 O
start 34 39 50 55 O
of 40 42 56 58 O
last 43 47 59 63 B-treatment
BMT 48 51 64 67 I-treatment

ALT 0 3 68 71 B-clinical_variable
, 3 4 71 72 O
AST 5 8 73 76 B-clinical_variable
, 8 9 76 77 O
and 10 13 78 81 O
Alkaline 14 22 82 90 B-clinical_variable
Phosphatase 23 34 91 102 I-clinical_variable
< 35 36 103 104 O
5 37 38 105 106 B-upper_bound
x 39 40 107 108 I-upper_bound
ULN 41 44 109 112 I-upper_bound

Age 0 3 113 116 B-age
> 4 5 117 118 O
0.5 5 8 118 121 B-lower_bound
years 9 14 122 127 I-lower_bound

Any 0 3 128 131 O
other 4 9 132 137 O
solid 10 15 138 143 B-cancer
tumor 16 21 144 149 I-cancer
and 22 25 150 153 O
soft 26 30 154 158 B-cancer
tissue 31 37 159 165 I-cancer
sarcoma 38 45 166 173 I-cancer
with 46 50 174 178 O
an 51 53 179 181 O
estimated 54 63 182 191 O
< 64 65 192 193 O
10 65 67 193 195 B-upper_bound
% 67 68 195 196 I-upper_bound
chance 69 75 197 203 O
of 76 78 204 206 O
survival 79 87 207 215 O
will 88 92 216 220 O
be 93 95 221 223 O
considered 96 106 224 234 O
on 107 109 235 237 O
a 110 111 238 239 O
case 112 116 240 244 O
by 117 119 245 247 O
case 120 124 248 252 O
basis 125 130 253 258 O
at 131 133 259 261 O
the 134 137 262 265 O
departmental 138 150 266 278 O
tumor 151 156 279 284 O
board 157 162 285 290 O
and/or 163 169 291 297 O
sarcoma 170 177 298 305 O
meeting 178 185 306 313 O

Bilirubin 0 9 314 323 B-clinical_variable
≤ 10 11 324 325 O
3.0 12 15 326 329 B-upper_bound
mg 16 18 330 332 I-upper_bound
/ 18 19 332 333 I-upper_bound
dL 19 21 333 335 I-upper_bound

Cardiac 0 7 336 343 B-chronic_disease

Desmoplastic 0 12 344 356 B-cancer
small 13 18 357 362 I-cancer
round 19 24 363 368 I-cancer
cell 25 29 369 373 I-cancer
tumor 30 35 374 379 I-cancer

FEV1 0 4 380 384 B-clinical_variable
, 4 5 384 385 O
FVC 6 9 386 389 B-clinical_variable
, 9 10 389 390 O
DLCO 11 15 391 395 B-clinical_variable
( 16 17 396 397 O
diffusion 17 26 397 406 B-clinical_variable
capacity 27 35 407 415 I-clinical_variable
) 35 36 415 416 O
> 37 38 417 418 O
50 39 41 419 421 B-lower_bound
% 41 42 421 422 I-lower_bound
predicted 43 52 423 432 O
( 53 54 433 434 O
corrected 54 63 434 443 O
for 64 67 444 447 O
hemoglobin 68 78 448 458 B-clinical_variable
) 78 79 458 459 O

Failure 0 7 460 467 O
to 8 10 468 470 O
achieve 11 18 471 478 O
at 19 21 479 481 O
least 22 27 482 487 O
a 28 29 488 489 O
PR 30 32 490 492 O
after 33 38 493 498 O
induction 39 48 499 508 B-treatment
therapy 49 56 509 516 I-treatment
with 57 61 517 521 I-treatment
COG 62 65 522 525 I-treatment
ANBL0532 66 74 526 534 I-treatment
or 75 77 535 537 O
standard 78 86 538 546 B-treatment
chemotherapy 87 99 547 559 I-treatment

For 0 3 560 563 O
CMV 4 7 564 567 B-chronic_disease
seronegative 8 20 568 580 O
recipients 21 31 581 591 O
, 31 32 591 592 O
a 33 34 593 594 O
CMV 35 38 595 598 O
seronegative 39 51 599 611 O
donor 52 57 612 617 O

Good 0 4 618 622 O
performance 5 16 623 634 O
status 17 23 635 641 O
( 24 25 642 643 O
Karnofsky 25 34 643 652 B-clinical_variable
/ 34 35 652 653 O
Lansky 35 41 653 659 B-clinical_variable
60 42 44 660 662 B-lower_bound
- 44 45 662 663 O
100 45 48 663 666 B-upper_bound
) 48 49 666 667 O

HIV 0 3 668 671 B-chronic_disease
- 3 4 671 672 O
positive 4 12 672 680 O

HLA 0 3 681 684 B-treatment
- 3 4 684 685 O
mismatched 4 14 685 695 O
donors 15 21 696 702 O
will 22 26 703 707 O
be 27 29 708 710 O
prioritized 30 41 711 722 O
over 42 46 723 727 O
HLA 47 50 728 731 O
- 50 51 731 732 O
matched 51 58 732 739 O
to 59 61 740 742 O
maximize 62 70 743 751 O
an 71 73 752 754 O
allogeneic 74 84 755 765 O
benefit 85 92 766 773 O

Hepatic 0 7 774 781 B-chronic_disease

It 0 2 782 784 O
is 3 5 785 787 O
expected 6 14 788 796 O
that 15 19 797 801 O
patients 20 28 802 810 O
will 29 33 811 815 O
have 34 38 816 820 O
received 39 47 821 829 O
upfront 48 55 830 837 O
standard 56 64 838 846 O
of 65 67 847 849 O
care 68 72 850 854 O
therapy 73 80 855 862 B-treatment
for 81 84 863 866 O
their 85 90 867 872 O
respected 91 100 873 882 O
disease 101 108 883 890 O

Left 0 4 891 895 B-clinical_variable
ventricular 5 16 896 907 I-clinical_variable
ejection 17 25 908 916 I-clinical_variable
fraction 26 34 917 925 I-clinical_variable
at 35 37 926 928 O
rest 38 42 929 933 O
must 43 47 934 938 O
be 48 50 939 941 O
≥ 51 52 942 943 O
35 53 55 944 946 B-lower_bound
% 55 56 946 947 I-lower_bound

Major 0 5 948 953 O
ABO 6 9 954 957 B-chronic_disease
incompatibility 10 25 958 973 I-chronic_disease

Metastatic 0 10 974 984 B-cancer
Ewing 11 16 985 990 I-cancer
Sarcoma 17 24 991 998 I-cancer

Minor 0 5 999 1004 O
ABO 6 9 1005 1008 B-chronic_disease
incompatibility 10 25 1009 1024 I-chronic_disease

Neuroblastoma 0 13 1025 1038 B-cancer

Osteosarcoma 0 12 1039 1051 B-cancer
with 13 17 1052 1056 O
metastatic 18 28 1057 1067 O
disease 29 36 1068 1075 O
beyond 37 43 1076 1082 O
the 44 47 1083 1086 O
lungs 48 53 1087 1092 O

Patients 0 8 1093 1101 O
( 9 10 1102 1103 O
Parents 10 17 1103 1110 O
/ 17 18 1110 1111 O
guardians 18 27 1111 1120 O
for 28 31 1121 1124 O
those 32 37 1125 1130 O
< 38 39 1131 1132 O
18 39 41 1132 1134 B-upper_bound
) 41 42 1134 1135 O
and 43 46 1136 1139 O
donors 47 53 1140 1146 O
must 54 58 1147 1151 O
be 59 61 1152 1154 O
able 62 66 1155 1159 O
to 67 69 1160 1162 O
sign 70 74 1163 1167 O
consent 75 82 1168 1175 O
forms 83 88 1176 1181 O

Patients 0 8 1182 1190 O
must 9 13 1191 1195 O
be 14 16 1196 1198 O
recovered 17 26 1199 1208 O
from 27 31 1209 1213 O
the 32 35 1214 1217 O
acute 36 41 1218 1223 O
toxicities 42 52 1224 1234 O
of 53 55 1235 1237 O
any 56 59 1238 1241 O
prior 60 65 1242 1247 B-treatment
chemo 66 71 1248 1253 I-treatment
/ 71 72 1253 1254 O
radio 72 77 1254 1259 B-treatment
/ 77 78 1259 1260 O
immunotherapy 78 91 1260 1273 B-treatment
or 92 94 1274 1276 O
BMT 95 98 1277 1280 B-treatment

Patients 0 8 1281 1289 O
must 9 13 1290 1294 O
be 14 16 1295 1297 O
willing 17 24 1298 1305 O
to 25 27 1306 1308 O
participate 28 39 1309 1320 O
in 40 42 1321 1323 O
all 43 46 1324 1327 O
stages 47 53 1328 1334 O
of 54 56 1335 1337 O
treatment 57 66 1338 1347 B-treatment

Patients 0 8 1348 1356 O
who 9 12 1357 1360 O
relapse 13 20 1361 1368 O
after 21 26 1369 1374 O
either 27 33 1375 1381 O
single 34 40 1382 1388 O
or 41 43 1389 1391 O
tandem 44 50 1392 1398 O
autologous 51 61 1399 1409 B-treatment
BMT 62 65 1410 1413 I-treatment
are 66 69 1414 1417 O
eligible 70 78 1418 1426 O

Patients 0 8 1427 1435 O
with 9 13 1436 1440 O
> 14 15 1441 1442 O
5 15 16 1442 1443 B-lower_bound
identified 17 27 1444 1454 O
lesions 28 35 1455 1462 B-clinical_variable
on 36 38 1463 1465 O
the 39 42 1466 1469 O
end 43 46 1470 1473 O
of 47 49 1474 1476 O
induction 50 59 1477 1486 B-treatment
( 60 61 1487 1488 O
COG 61 64 1488 1491 B-treatment
ANBL0532 65 73 1492 1500 I-treatment
or 74 76 1501 1503 O
standard 77 85 1504 1512 B-treatment
chemotherapy 86 98 1513 1525 I-treatment
) 98 99 1525 1526 O
MIBG 100 104 1527 1531 B-treatment
scan 105 109 1532 1536 I-treatment

Patients 0 8 1537 1545 O
with 9 13 1546 1550 O
high 14 18 1551 1555 O
risk 19 23 1556 1560 O
disease 24 31 1561 1568 O
as 32 34 1569 1571 O
defined 35 42 1572 1579 O
in 43 45 1580 1582 O
Appendix 46 54 1583 1591 O
1 55 56 1592 1593 O
who 57 60 1594 1597 O
do 61 63 1598 1600 O
not 64 67 1601 1604 O
meet 68 72 1605 1609 O
eligibility 73 84 1610 1621 O
requirements 85 97 1622 1634 O
/ 97 98 1634 1635 O
organ 98 103 1635 1640 O
function 104 112 1641 1649 O
requirements 113 125 1650 1662 O
for 126 129 1663 1666 O
myeloablative 130 143 1667 1680 B-chronic_disease
conditioning 144 156 1681 1693 O

Patients 0 8 1694 1702 O
with 9 13 1703 1707 O
high 14 18 1708 1712 O
risk 19 23 1713 1717 O
disease 24 31 1718 1725 O
as 32 34 1726 1728 O
defined 35 42 1729 1736 O
in 43 45 1737 1739 O
Appendix 46 54 1740 1748 O
1 55 56 1749 1750 O
whose 57 62 1751 1756 O
autologous 63 73 1757 1767 O
peripheral 74 84 1768 1778 O
blood 85 90 1779 1784 O
stem 91 95 1785 1789 O
cell 96 100 1790 1794 O
product 101 108 1795 1802 O
is 109 111 1803 1805 O
contaminated 112 124 1806 1818 O
with 125 129 1819 1823 O
neuroblastoma 130 143 1824 1837 B-cancer
or 144 146 1838 1840 O
who 147 150 1841 1844 O
do 151 153 1845 1847 O
not 154 157 1848 1851 O
have 158 162 1852 1856 O
an 163 165 1857 1859 O
autologous 166 176 1860 1870 O
product 177 184 1871 1878 O
available 185 194 1879 1888 O

Patients 0 8 1889 1897 O
with 9 13 1898 1902 O
measurable 14 24 1903 1913 O
disease 25 32 1914 1921 O
must 33 37 1922 1926 O
have 38 42 1927 1931 O
stable 43 49 1932 1938 O
disease 50 57 1939 1946 O
by 58 60 1947 1949 O
RECIST 61 67 1950 1956 O
criteria 68 76 1957 1965 O
on 77 79 1966 1968 O
two 80 83 1969 1972 O
scans 84 89 1973 1978 O
at 90 92 1979 1981 O
least 93 98 1982 1987 O
6 99 100 1988 1989 B-lower_bound
weeks 101 106 1990 1995 I-lower_bound
apart 107 112 1996 2001 O

Positive 0 8 2002 2010 O
leukocytotoxic 9 23 2011 2025 B-treatment
crossmatch 24 34 2026 2036 I-treatment

Refractory 0 10 2037 2047 O
to 11 13 2048 2050 O
induction 14 23 2051 2060 B-treatment
chemotherapy 24 36 2061 2073 I-treatment
with 37 41 2074 2078 O
COG 42 45 2079 2082 B-treatment
ANBL0532 46 54 2083 2091 I-treatment
or 55 57 2092 2094 O
standard 58 66 2095 2103 B-treatment
chemotherapy 67 79 2104 2116 I-treatment

Serum 0 5 2117 2122 B-clinical_variable
creatinine 6 16 2123 2133 I-clinical_variable
within 17 23 2134 2140 O
normal 24 30 2141 2147 O
range 31 36 2148 2153 O
for 37 40 2154 2157 O
age 41 44 2158 2161 B-age

Stage 0 5 2162 2167 B-cancer
4 6 7 2168 2169 I-cancer
rhabdomyosarcoma 8 24 2170 2186 I-cancer

The 0 3 2187 2190 O
donor 4 9 2191 2196 O
and 10 13 2197 2200 O
recipient 14 23 2201 2210 O
must 24 28 2211 2215 O
be 29 31 2216 2218 O
identical 32 41 2219 2228 O
at 42 44 2229 2231 O
at 45 47 2232 2234 O
least 48 53 2235 2240 O
one 54 57 2241 2244 B-lower_bound
allele 58 64 2245 2251 O
of 65 67 2252 2254 O
each 68 72 2255 2259 O
of 73 75 2260 2262 O
the 76 79 2263 2266 O
following 80 89 2267 2276 O
genetic 90 97 2277 2284 O
loci 98 102 2285 2289 O
: 102 103 2289 2290 O
HLA 104 107 2291 2294 O
- 107 108 2294 2295 O
A 108 109 2295 2296 O
, 109 110 2296 2297 O
HLA 111 114 2298 2301 O
- 114 115 2301 2302 O
B 115 116 2302 2303 O
, 116 117 2303 2304 O
HLA 118 121 2305 2308 O
- 121 122 2308 2309 O
Cw 122 124 2309 2311 O
, 124 125 2311 2312 O
HLA 126 129 2313 2316 O
- 129 130 2316 2317 O
DRB1 130 134 2317 2321 O
, 134 135 2321 2322 O
and 136 139 2323 2326 O
HLA 140 143 2327 2330 O
- 143 144 2330 2331 O
DQB1 144 148 2331 2335 O

Uncontrolled 0 12 2336 2348 O
viral 13 18 2349 2354 B-chronic_disease
, 18 19 2354 2355 O
bacterial 20 29 2356 2365 B-chronic_disease
, 29 30 2365 2366 O
or 31 33 2367 2369 O
fungal 34 40 2370 2376 B-chronic_disease
infections 41 51 2377 2387 I-chronic_disease

Women 0 5 2388 2393 B-gender
of 6 8 2394 2396 O
childbearing 9 21 2397 2409 O
potential 22 31 2410 2419 O
who 32 35 2420 2423 O
currently 36 45 2424 2433 O
are 46 49 2434 2437 B-pregnancy
pregnant 50 58 2438 2446 I-pregnancy
( 59 60 2447 2448 O
HCG+ 60 64 2448 2452 B-clinical_variable
) 64 65 2452 2453 O

be 0 2 2454 2456 O
classified 3 13 2457 2467 O
as 14 16 2468 2470 O
high 17 21 2471 2475 O
risk 22 26 2476 2480 O
defined 27 34 2481 2488 O
by 35 37 2489 2491 O
having 38 44 2492 2498 O
an 45 47 2499 2501 O
expected 48 56 2502 2510 B-clinical_variable
survival 57 65 2511 2519 I-clinical_variable
of 66 68 2520 2522 O
< 69 70 2523 2524 O
10 71 73 2525 2527 B-upper_bound
% 73 74 2527 2528 I-upper_bound

ganglioneuroblastoma 0 20 2529 2549 B-cancer

shortening 0 10 2550 2560 B-clinical_variable
fraction 11 19 2561 2569 I-clinical_variable
> 20 21 2570 2571 O
25 22 24 2572 2574 B-lower_bound
% 24 25 2574 2575 I-lower_bound

who 0 3 2576 2579 O
are 4 7 2580 2583 O
not 8 11 2584 2587 O
practicing 12 22 2588 2598 B-contraception_consent
adequate 23 31 2599 2607 I-contraception_consent
contraception 32 45 2608 2621 I-contraception_consent

with 0 4 2622 2626 O
lung 5 9 2627 2631 B-cancer
metastases 10 20 2632 2642 I-cancer
not 21 24 2643 2646 O
amenable 25 33 2647 2655 O
to 34 36 2656 2658 O
resection 37 46 2659 2668 B-treatment

